Examples of Korean Company in a sentence
POSCO Power hereby grants to FCE a non-exclusive paid-up license to manufacture, use and sell POSCO Technology during the Term; provided, however, that the FCE Products incorporate POSCO Technology under all patents of all countries under which POSCO Power during the Term, has or may acquire, the right to grant such licenses, and provided, further, that any sublicensing or resale by FCE of POSCO Technology to any Korean Company shall be subject to POSCO Power’s sole discretion.
According to the license agreement, the Company granted the Korean Company a license to use, develop and market its CF101 drug for treating only rheumatoid arthritis only in the Republic of Korea.
Miscellaneous Shareholders N/A 78,234,054 ordinary shares 54,027,794 shares 134,330,848 ordinary shares(including 2,079,000 treasury shares) 59.15% 40.85% None Record Owner No. of Shares or No. of Shares or No. Shares Covered Type of (Beneficial Owner, Interests Interests Percentage by Warrants; Issuer Organization if different) Certificate No. Owned Outstanding Ownership Options Novelis Korea Limited Korean Company, Limited 4260856 Canada Inc.
Miscellaneous Shareholders N/A 78,234,054 ordinary shares 54,027,794 shares 134,330,848 ordinary shares(including 2,079,000 treasury shares) 59.15 40.85 % % None Record Owner No. of Shares or No. of Shares or No. Shares Covered (Beneficial Owner, Interests Interests by Warrants; Issuer Type of Organization if different) Certificate No. Owned Outstanding Percentage Ownership Options Novelis Korea Limited Korean Company, Limited 4260856 Canada Inc.
The Company is entitled to annual royalties of 7% based on sales of CF101 in Korea as marketed by the Korean Company according to the Korean License Agreement.- 12 - NOTES TO INTERIM CONDENSED CONSOLIDATED STATEMENTS (UNAUDITED) NOTE 3:- CONTINGENT LIABILITIES AND COMMITMENTS (Cont.)As of December 31, 2015, and as of June 30, 2016, the Company estimates that such contingent payments are remote.
At any time that the Company proposes to register with the FSC, or list on the Korea Stock Exchange or KOSDAQ, any Equity Securities for sale solely for cash, for its own account, for the account of a stockholder or stockholders (including pursuant to Section 2), or both (a "Korean Company Registration"), the Company shall give the Holders prompt written notice of its intention to do so and of the intended method of sale (the "Korean Registration Notice").
The Company is entitled to annual royalties of 7% based on sales of CF101 in Korea as marketed by the Korean Company according to the Korean License Agreement.As of June 30, 2014, the Company estimates that such contingent payments are remote.
The Company shall use its best efforts to cause all Registrable Securities specified in the Korean Piggyback Notice(s) to be included in the Korean Company Registration and any related offering, all to the extent requisite to permit the sale by the participating Holders of such Registrable Securities in accordance with the method of sale applicable to the other Equity Securities included in the Korean Company Registration.
According to the license agreement, the Company granted the Korean Company a license to use, develop and market its Piclidenoson drug for treating only rheumatoid arthritis only in the Republic of Korea.
Miscellaneous Shareholders N/A 78,234,054 ordinary shares 54,027,794 shares 134,330,848 ordinary shares (including 2,079,000 treasury shares) 59.15% 40.85% None Novelis Korea Limited Korean Company, Limited 4260856 Canada Inc.